Siren L.L.C. Reduces Holdings in Gossamer Bio, Inc. $GOSS

Key Points

• Siren L.L.C. reduced its stake in Gossamer Bio by 3.8%, now holding about 5.2 million shares valued at approximately $5.73 million.
• Gossamer Bio's stock has seen a 12.3% increase recently, trading at $3.11 with a market capitalization of $707.15 million.
• Analysts have mixed views on Gossamer Bio, with a consensus target price of $8.50 and varying ratings from "buy" to "sell" across different brokerages.

Siren L.L.C. cut its stake in Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 3.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,208,968 shares of the company's stock after selling 207,000 shares during the period. Siren L.L.C. owned approximately 2.29% of Gossamer Bio worth $5,730,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. Acadian Asset Management LLC grew its position in shares of Gossamer Bio by 24.6% in the first quarter. Acadian Asset Management LLC now owns 6,358,113 shares of the company's stock valued at $6,991,000 after purchasing an additional 1,253,353 shares in the last quarter. Two Sigma Investments LP grew its position in shares of Gossamer Bio by 41.3% in the fourth quarter. Two Sigma Investments LP now owns 891,279 shares of the company's stock valued at $806,000 after purchasing an additional 260,318 shares in the last quarter. OMERS ADMINISTRATION Corp purchased a new stake in shares of Gossamer Bio in the first quarter valued at approximately $387,000. Two Sigma Advisers LP grew its position in shares of Gossamer Bio by 44.7% in the fourth quarter. Two Sigma Advisers LP now owns 1,157,500 shares of the company's stock valued at $1,047,000 after purchasing an additional 357,500 shares in the last quarter. Finally, Mackenzie Financial Corp grew its position in shares of Gossamer Bio by 499.0% in the fourth quarter. Mackenzie Financial Corp now owns 299,815 shares of the company's stock valued at $271,000 after purchasing an additional 249,765 shares in the last quarter. 81.23% of the stock is currently owned by hedge funds and other institutional investors.

Gossamer Bio Stock Up 0.5%

Gossamer Bio stock traded up $0.02 during midday trading on Tuesday, reaching $3.20. The company's stock had a trading volume of 1,990,343 shares, compared to its average volume of 2,223,679. Gossamer Bio, Inc. has a fifty-two week low of $0.66 and a fifty-two week high of $3.60. The company has a quick ratio of 4.40, a current ratio of 4.40 and a debt-to-equity ratio of 6.70. The company has a market cap of $726.48 million, a P/E ratio of -5.15 and a beta of 1.95. The business has a 50-day simple moving average of $2.12 and a 200-day simple moving average of $1.48.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.18) by $0.01. Gossamer Bio had a negative return on equity of 1,774.72% and a negative net margin of 344.81%.The company had revenue of $11.49 million for the quarter, compared to analysts' expectations of $4.12 million. On average, research analysts expect that Gossamer Bio, Inc. will post -0.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on GOSS. Scotiabank began coverage on Gossamer Bio in a research report on Monday, July 14th. They issued a "sector outperform" rating and a $11.00 price objective for the company. Cantor Fitzgerald reiterated an "overweight" rating on shares of Gossamer Bio in a research report on Thursday, September 11th. Wedbush increased their price objective on Gossamer Bio from $4.00 to $5.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 6th. Finally, Wall Street Zen upgraded Gossamer Bio from a "sell" rating to a "hold" rating in a research report on Saturday. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $8.50.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.